High-Dose Treosulfan and Melphalan Consolidation Therapy vs Standard Therapy for High-Risk Metastatic Ewing Sarcoma
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Journal of Clinical Oncology
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
High-Dose Treosulfan and Melphalan as Consolidation Therapy Versus Standard Therapy for High-Risk (Metastatic) Ewing Sarcoma
J. Clin. Oncol 2022 Apr 15;[EPub Ahead of Print], R Koch, H Gelderblom, L Haveman, B Brichard, H Jürgens, S Cyprova, H van den Berg, W Hassenpflug, A Raciborska, T Ek, D Baumhoer, G Egerer, HT Eich, M Renard, P Hauser, S Burdach, J Bovee, F Bonar, P Reichardt, J Kruseova, J Hardes, T Kühne, T Kessler, S Collaud, M Bernkopf, T Butterfaß-Bahloul, C Dhooge, S Bauer, J Kiss, M Paulussen, A Hong, A Ranft, B Timmermann, J Rascon, V Vieth, J Kanerva, A Faldum, M Metzler, W Hartmann, L Hjorth, V Bhadri, U DirksenFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.